Shots: The approval is based on P-III ATTR-ACT study assessing Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) vs PBO in patients with ATTR-CM The P-III ATTR-ACT study results: @30mos. reduction in […]readmore
Tags : tafamidis meglumine